Bai Yifeng, Wang Jirui, Song Linsheng, Hu Honglin, Yang Lan, Feng Gang, Chen Jie, Peng Heling, Peng Shengkun
Department of Oncology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610071, Sichuan Province, China.
Department of Radiology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610071, Sichuan Province, China.
J Cancer. 2025 Jul 28;16(12):3579-3588. doi: 10.7150/jca.116142. eCollection 2025.
To evaluate the impact of Huisheng Oral Solution (HSOS) in conjunction with immune checkpoint inhibitors (ICIs) and chemotherapy on patients with stage III-IV non-small cell lung cancer (NSCLC). This retrospective study included patients with stage III-IV NSCLC who were treated at Sichuan Provincial People's Hospital from May 2018 to June 2021. Patients were categorized into two groups: the ICIs & Chemo Group and the ICIs & Chemo & HSOS Group, based on the therapies administered. The disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and immune-related adverse events (irAEs) were assessed. A total of 185 patients were included, with 109 patients in ICIs & Chemo & HSOS Group. The ICIs & Chemo & HSOS Group exhibited significantly enhanced DCR (90.83% vs. 71.05%, p=0.001) compared to the ICIs & Chemo Group. The ORR was not statistically significant between the two groups (31.19% vs. 27.63%, p=0.628). Patients in the ICIs & Chemo & HSOS Group had significantly longer PFS (HR=0.47, 95% CI: 0.29-0.75, p<0.001) and OS (HR=0.58, 95% CI: 0.33-1.00, p=0.037) than the ICIs & Chemo Group. In terms of irAEs, nephrotoxicity (5.77% vs. 15.25%, p=0.044), checkpoint inhibitor-related pneumonitis (CIP) (2.75% vs. 11.84%, p=0.014), and cardiotoxicity (0% vs. 13.04%, p=0.026) were significantly lower in the ICIs & Chemo & HSOS Group. The addition of HSOS to ICIs and chemotherapy may enhance DCR, PFS, and OS, while concurrently reducing irAEs in patients with stage III-IV NSCLC. These findings suggest that HSOS may serve as a promising adjunct to ICI-based therapies. Further prospective studies are warranted to validate these results.
评估回生口服液（HSOS）联合免疫检查点抑制剂（ICIs）及化疗对Ⅲ-Ⅳ期非小细胞肺癌（NSCLC）患者的影响。这项回顾性研究纳入了2018年5月至2021年6月在四川省人民医院接受治疗的Ⅲ-Ⅳ期NSCLC患者。根据所接受的治疗方法，将患者分为两组：ICIs与化疗组和ICIs与化疗及HSOS组。评估疾病控制率（DCR）、客观缓解率（ORR）、无进展生存期（PFS）、总生存期（OS）及免疫相关不良事件（irAEs）。共纳入185例患者，其中109例在ICIs与化疗及HSOS组。与ICIs与化疗组相比，ICIs与化疗及HSOS组的DCR显著提高（90.83%对71.05%，p = 0.001）。两组间的ORR无统计学差异（31.19%对27.63%，p = 0.628）。ICIs与化疗及HSOS组患者的PFS（HR = 0.47，95%CI：0.29 - 0.75，p < 0.001）和OS（HR = 0.58，95%CI：0.33 - 1.00，p = 0.037）显著长于ICIs与化疗组。在irAEs方面，ICIs与化疗及HSOS组的肾毒性（5.77%对15.25%，p = 0.044）、检查点抑制剂相关肺炎（CIP）（2.75%对11.84%，p = 0.014）和心脏毒性（0%对13.04%，p = 0.026）显著更低。在ICIs和化疗中加入HSOS可能提高Ⅲ-Ⅳ期NSCLC患者的DCR、PFS和OS，同时降低irAEs。这些发现表明HSOS可能是基于ICI治疗的一种有前景的辅助药物。有必要进行进一步的前瞻性研究来验证这些结果。
